News and Press Releases
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting
2 June 2024 -- Utrecht, The Netherlands and Massachusetts, US -- Merus NV, a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced updated interim clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 2, 2024
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
Submission is supported by data from the phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting New formulation showed non-inferiority to intravenous administration in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 31, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
RYBREVANT▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark phase 3 MARIPOSA data featured in an oral...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 31, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
23 May 2024 -- Tokyo, Japan -- Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American...
Category: Clinical Trials, Drug Discovery
Posted: May 23, 2024
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis
China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has...
Category: Biotechnology, Clinical Trials
Posted: May 22, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Johnson & Johnson receives positive CHMP opinion for RYBREVANT▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC The recommendation is...
Category: Clinical Trials, Pharmaceutical
Posted: April 29, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting
Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...
Category: Pharmaceutical
Posted: April 8, 2024
Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is...
Category: Pharmaceutical
Posted: April 8, 2024
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study
The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a...
Category: Biotechnology, Clinical Trials
Posted: April 3, 2024
